Hematology

The FDA's approval of ibrutinib February 12 for the second-line treatment of patients with chronic lymphocytic leukemia (CLL) was exciting news indeed for thousands of patients with CLL who stand to benefit from the drug

Several trials of ibrutinib, an oral kinase inhibitor, either alone or in combination with currently used therapies for patients with chronic lymphocytic leukemia were presented at the 2013 ASH annual meeting.

A higher cumulative dose of the proteasome inhibitor bortezomib, including a longer duration of treatment and/or higher dose intensity, appears to improve overall survival in patients with previously untreated multiple myeloma

The FDA has granted an accelerated approval to ibrutinib (Imbruvica) as a treatment for patients with chronic lymphocytic leukemia

It is important for oncologists to monitor, design, and administer appropriate bone health treatments at the earliest stages for the 80% to 90% of patients with multiple myeloma who develop osteolytic bone lesions.

Older patients with advanced hematologic malignancies who receive a minimally toxic nonmyeloablative regimen before allogeneic HCT have favorable OS and PFS rates.

Because of bendamustine's potential to cause pain and erythema to the extent that hospitalization has been required for some patients, it would be prudent to administer bendamustine using vesicant precautions.

Myelodysplastic syndromes (MDS) are a group of hematological conditions affecting the blood stem cells in the bone marrow.

In 2001, Doug Rickert, a 46-year-old industrial management consultant and married father of 3, heard the life-altering words, "softball-sized tumor pressing against your spinal canal."

Two small genetic variations predict which patients are most likely to develop second cancers.

Reynaldo Garcia From Lineberger Comprehensive Cancer Center on CML BCR-ABL Testing Recommendation

Reynaldo Garcia from the University of North Carolina Lineberger Comprehensive Cancer Center on BCR-ABL Testing in Chronic Myelogenous Leukemia

The FDA is examining a potential link between breast implants and anaplastic large cell lymphoma (ALCL), a rare and aggressive form of non-Hodgkin lymphoma.

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States

Siddhartha Mukherjee, MD, discusses his book The Emperor of All Maladies.